This approval was based on the results of the SOYAYA study, which examined high-FRα-expressing, platinum-resistant epithelial ovarian, fallopian, or primary peritoneal cancers in patients who had received one to three previous systemic therapies [36]. Here, FOLR1 is linked to peritoneum cancer.